New combo therapy aims to cure hepatitis b in over half of patients
NCT ID NCT05769816
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tests a new combination of an anti-PD-1 antibody (a type of immunotherapy) plus standard antiviral drugs in 120 adults with chronic hepatitis B. The goal is to achieve a functional cure, where the virus is no longer active and patients can stop medication. The study builds on earlier work that achieved cure in up to 50% of certain patients, and aims to improve that rate to over 50% overall.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anti-PD-1 antibody (a type of immunotherapy) and nucleos(t)ide analogues (antiviral drugs)
- What this could lead to
- If successful, this combination could help more than half of patients achieve a functional cure, meaning the virus is controlled without lifelong medication.
- What could go wrong
- This is a phase 2 trial with only 120 participants, so results are preliminary. The anti-PD-1 antibody may cause immune-related side effects, and the cure rate may not reach the hoped-for 50%.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTI-PD-1 ANTIBODY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The 2nd affiliated Hospital of Chongqing Medical University
RECRUITINGChongqing, Chongqing Municipality, 400010, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple scan and blood test outsmart liver cancer?
- Can a new injection tame chronic hepatitis b?
- Double liver trouble: does having both hepatitis b and fatty liver speed up disease?
- A second punch against hepatitis b: interferon after RNA drugs may clear the virus
- Could common hepatitis b drugs damage kidneys? a study digs into the data
- Can fatty liver and hepatitis b together harm kidneys? a study digs into the data